Innoviva, Inc. (INVA): Price and Financial Metrics

Innoviva, Inc. (INVA): $15.46

-0.89 (-5.44%)

POWR Rating

Component Grades













Add INVA to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where INVA ranks best; there it ranks ahead of 94.02% of US stocks.
  • INVA's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • INVA's current lowest rank is in the Sentiment metric (where it is better than 5.55% of US stocks).

INVA Stock Summary

  • INVA's current price/earnings ratio is 5.15, which is higher than only 7% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for Innoviva Inc is higher than it is for about 96.88% of US stocks.
  • Innoviva Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 28.69%, greater than the shareholder yield of 94.31% of stocks in our set.
  • Stocks that are quantitatively similar to INVA, based on their financial statements, market capitalization, and price volatility, are TRN, PBF, ORA, LXU, and VGR.
  • Visit INVA's SEC page to see the company's official filings. To visit the company's web site, go to

INVA Valuation Summary

  • INVA's price/earnings ratio is 4; this is 89.04% lower than that of the median Healthcare stock.
  • Over the past 206 months, INVA's price/sales ratio has gone down 124.5.
  • Over the past 206 months, INVA's EV/EBIT ratio has gone up 11.2.

Below are key valuation metrics over time for INVA.

Stock Date P/S P/B P/E EV/EBIT
INVA 2021-08-31 2.9 3.2 4.0 4.0
INVA 2021-08-30 2.9 3.2 4.0 4.0
INVA 2021-08-27 2.8 3.1 3.8 3.9
INVA 2021-08-26 2.8 3.1 3.8 3.8
INVA 2021-08-25 2.8 3.1 3.9 3.9
INVA 2021-08-24 3.0 3.3 4.1 4.1

INVA Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 1197%.
  • Its 4 year revenue growth rate is now at 299.43%.
  • Its year over year revenue growth rate is now at 20.78%.
INVA's revenue has moved up $128,059,000 over the prior 34 months.

The table below shows INVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 391.866 363.813 265.854
2021-09-30 374.662 350.712 309.412
2021-06-30 365.494 328.559 265.192
2021-03-31 343.634 323.739 253.088
2020-12-31 336.794 313.113 224.402
2020-09-30 322.289 294.738 216.448

INVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INVA has a Quality Grade of B, ranking ahead of 77.13% of graded US stocks.
  • INVA's asset turnover comes in at 0.398 -- ranking 118th of 682 Pharmaceutical Products stocks.
  • LUMO, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with INVA.

The table below shows INVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.398 1 0.357
2021-06-30 0.385 1 0.331
2021-03-31 0.353 1 0.337
2020-12-31 0.375 1 0.336
2020-09-30 0.389 1 0.354
2020-06-30 0.390 1 0.363

INVA Price Target

For more insight on analysts targets of INVA, see our INVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 2.5 (Moderate Sell)

INVA Stock Price Chart Interactive Chart >

Price chart for INVA

INVA Price/Volume Stats

Current price $15.46 52-week high $20.71
Prev. close $16.35 52-week low $12.14
Day low $15.43 Volume 1,081,307
Day high $16.08 Avg. volume 1,115,780
50-day MA $17.82 Dividend yield N/A
200-day MA $17.12 Market Cap 1.08B

Innoviva, Inc. (INVA) Company Bio

Innoviva is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. The company was founded in 1996 and is based in South San Francisco, California.

INVA Latest News Stream

Event/Time News Detail
Loading, please wait...

INVA Latest Social Stream

Loading social stream, please wait...

View Full INVA Social Stream

Latest INVA News From Around the Web

Below are the latest news stories about Innoviva Inc that investors may wish to consider to help them evaluate INVA as an investment opportunity.

Can Innoviva (INVA) Run Higher on Rising Earnings Estimates?

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Yahoo | February 24, 2022

Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?

Here is how Innoviva (INVA) and Phibro Animal Health (PAHC) have performed compared to their sector so far this year.

Yahoo | February 24, 2022

Taking Innoviva Winnings Off The Table, Again

Those who know me best know that my personality can be described as a blend of various odious traits that come to the fore at different times. On the one hand, I'm cowardly and am an inveterate braggart. On the other hand, I'm very lazy. These are in some conflict...

Patrick Doyle on Seeking Alpha | February 21, 2022

Are Strong Financial Prospects The Force That Is Driving The Momentum In Innoviva, Inc.'s NASDAQ:INVA) Stock?

Innoviva's (NASDAQ:INVA) stock is up by a considerable 17% over the past week. Since the market usually pay for a...

Yahoo | February 11, 2022

Dermata, Innoviva top healthcare gainers; while InfuSystem, Seagen lead losers pack

Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem

Seeking Alpha | February 10, 2022

Read More 'INVA' Stories Here

INVA Price Returns

1-mo -13.29%
3-mo -19.35%
6-mo N/A
1-year 14.18%
3-year 6.55%
5-year 27.87%
YTD -10.38%
2021 39.23%
2020 -12.50%
2019 -18.85%
2018 22.97%
2017 32.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.617 seconds.